The clinical significance of CD97, NF-kB and COX-2 ingastric MALT lymphomas

Shao-Liang Han, Jun Cheng, Xiu-Ling Wu, Zeng-Rong Jia, Peng-Fei Wang, Zhan-Wei Wang

.

DOI: 10.4236/jbise.2011.47061                

Abstract

Background and Objectives: Increased expression of the CD97, nuclear factor-kB (NF-kB) and cyclooxygenase-2 (COX-2) has been found to play an important role in development of many cancers, including gastric neoplasm. However, the expression and biological behavior of CD97, NF-kB and COX-2 in gastric MALT (mucosa-associated lymphoid tissue) lymphoma has not been well investigated. Methods: The expressions of CD97, COX-2 and NF-kB in 47 cases of gastric MALT lymphoma were detected immunohistochemically, and the relevance between their expressions and the biological behavior was analyzed retrospectively. Results: 1) The expressions of CD97, NF-kB and COX-2 were 87.2%, 36.2% and 48.9%, respectively; 2) The difference of CD97 expression between depth of invasion limited in mucosa and submucosa and beyond muscularis propria was significant (100.0% vs. 71.4%, P < 0.01). Moreover, the expression of nuclear CD97 between stage IIE, III, IV and stage I patients showed significant difference (96.4% vs. 73.7%, P < 0.05); 3) The expression of NF-kB was significantly correlated with tumor size, depth of invasion and stage; 4) The expression of COX-2 was significantly correlated with Helicobacter pylori infection, clinical stage, depth of invasion and tumor size (P < 0.05). Conclusions: Expressions of CD97, NF-κB and COX-2 were correlated with tumor invasion and metastasis in gastric MALT lymphoma.

Keywords

Stomach Neoplasm; CD97; Nuclear Factor-Kb (NF-Kb); Cyclooxygenase-2 (COX-2); Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	Isaacson, P. and Wright, D.H. (1983) Malignant lymphoma of mucosa-associated lymphoid tissue. A distinctive type of B-cell lymphoma. Cancer, 52, 1410-1416. doi:10.1002/1097-0142(19831015)52:8<1410::AID-CNCR2820520813>3.0.CO;2-3
[2]	Isaacson, P.G. (2005) Update on MALT lymphomas. Best Practice & Research Clinical Haematology, 18, 57-68. doi:10.1016/j.beha.2004.08.003
[3]	Gascoyne, R.D. (2003) Molecular pathogenesis of mucosal-associated lymphoid tissue (MALT) lymphoma. Leukemia & Lymphoma, 44, S13-20. doi:10.1080/10428190310001623793
[4]	Harris, N.L., Jaffe, E.S., Diebold, J., et al. (1999) World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. Journal of Clinical Oncology, 17, 3835-3849.
[5]	Wotherspoon, A.C., Ortiz-Hidalgo, C., Falzon, M.R. and Isaacson, P.G. (1991) Helicobacter pylori-associated gastritis and primary B-cell gastric lymphoma. Lancet, 338, 1175-1176. doi:10.1016/0140-6736(91)92035-Z
[6]	Jaspars, L.H., Vos, W., Aust, G., et al. (2001) Tissue distribution of the human CD97 EGF-TM7 receptor. Tissue Antigens, 57, 325-331. doi:10.1034/j.1399-0039.2001.057004325.x
[7]	Wang, T., Ward, Y., Tian, L., et al. (2005) CD97, an adhesion receptor on inflammatory cells, stimulates angiogenesis through binding integrin counterreceptors on endothelial cells. Blood, 105, 2836-2844. doi:10.1182/blood-2004-07-2878
[8]	Aust, G., Eichler, W., Laue, S., et al. (1997) CD97: A dedifferentiation marker in human thyroid carcinomas. Cancer Research, 57, 1798-1806.
[9]	Aust, G., Steinert, M., Schutz, A., et al. (2002) CD97, but not its closely related EGF-TM7 family member EMR2, is expressed on gastric, pancreatic, and esophageal carcinomas. American Journal of Clinical Pathology, 118, 699-707. doi:10.1309/A6AB-VF3F-7M88-C0EJ
[10]	Galle, J., Sittig, D., Hanisch, I., et al. (2006) Individual cell-based models of tumor-environment interactions: Multiple effects of CD97 on tumor invasion. American Journal of Pathology, 169, 1802-1811. doi:10.2353/ajpath.2006.060006
[11]	Hoang-Vu, C., Bull, K., Schwarz, I., et al. (1999) Regulation of CD97 protein in thyroid carcinoma. The Journal of Clinical Endocrinology & Metabolism, 84, 1104-1109. doi:10.1210/jc.84.3.1104
[12]	Liu, Y., Chen, L., Peng, S.Y., et al. (2005) Role of CD97(stalk) and CD55 as molecular markers for prognosis and therapy of gastric carcinoma patients. Journal of Zhejiang University Science B, 6, 913-918. doi:10.1631/jzus.2005.B0913
[13]	Mustafa T, Klonisch T, Hombach-Klonisch S, et al.: Expression of CD97 and CD55 in human medullary thyroid carcinomas. Int J Oncol 2004;24:285-294.
[14]	Steinert, M., Wobus, M., Boltze, C., et al. (2002) Expression and regulation of CD97 in colorectal carcinoma cell lines and tumor tissues. American Journal of Pathology, 161, 1657-1667. doi:10.1016/S0002-9440(10)64443-4
[15]	Wobus, M., Huber, O., Hamann, J. and Aust, G. (2006) CD97 overexpression in tumor cells at the invasion front in colorectal cancer (CC) is independently regulated of the canonical Wnt pathway. Molecular Carcinogenesis, 45, 881-886. doi:10.1002/mc.20262
[16]	Claudio, E., Brown, K., Park, S., et al. (2002) BAFF-induced NEMO-independent processing of NF-kappa B2 in maturing B cells. Nature Immunology, 3, 958-965. doi:10.1038/ni842
[17]	Fu, L., Lin-Lee, Y.C., Pham, L.V., et al. (2006) Constitutive NF-kappaB and NFAT activation leads to stimulation of the BLyS survival pathway in aggressive B-cell lymphomas. Blood, 107, 4540-4548. doi:10.1182/blood-2005-10-4042
[18]	Hinz, M., Lemke, P., Anagnostopoulos, I., et al. (2002) Nuclear factor kappaB-dependent gene expression profiling of Hodgkin’s disease tumor cells, pathogenetic significance, and link to constitutive signal transducer and activator of transcription 5a activity. Journal of Experimental Medicine, 196, 605-617. doi:10.1084/jem.20020062
[19]	Hosokawa, Y. and Seto, M. (2004) Nuclear factor kappaB activation and antiapoptosis in mucosa-associated lymphoid tissue lymphoma. International Journal of Hematology, 80, 215-223. doi:10.1532/IJH97.04101
[20]	Jost, P.J. and Ruland, J. (2007) Aberrant NF-kappaB signaling in lymphoma: Mechanisms, consequences, and therapeutic implications. Blood, 109, 2700-2707.
[21]	Kaisho, T., Takeda, K., Tsujimura, T., et al. (2001) IkappaB kinase alpha is essential for mature B cell development and function. Journal of Experimental Medicine, 193, 417-426. doi:10.1084/jem.193.4.417
[22]	Karin, M. and Ben-Neriah, Y. (2000) Phosphorylation meets ubiquitination: The control of NF-[kappa]B activity. Annual Review of Immunology, 18, 621-663. doi:10.1146/annurev.immunol.18.1.621
[23]	Ohmae, T., Hirata, Y., Maeda, S., et al. (2005) Helicobacter pylori activates NF-kappaB via the alternative pathway in B lymphocytes. Journal of Immunology, 175, 7162-7169.
[24]	Senftleben, U., Cao, Y., Xiao, G., et al. (2001) Activation by IKKalpha of a second, evolutionary conserved, NF-kappa B signaling pathway. Science, 293, 1495-1499. doi:10.1126/science.1062677
[25]	Souvannavong, V., Saidji, N. and Chaby, R. (2007) Lipopolysaccharide from Salmonella enterica activates NF-kappaB through both classical and alternative pathways in primary B Lymphocytes. Infection and Immunity, 75, 4998-5003. doi:10.1128/IAI.00545-07
[26]	Kim, H.J., Hawke, N. and Baldwin, A.S. (2006) NF-kappaB and IKK as therapeutic targets in cancer. Cell Death & Differentiation, 13, 738-747. doi:10.1038/sj.cdd.4401877
[27]	Merzianu, M., Jiang, L., Lin, P., et al. (2006) Nuclear BCL-10 expression is common in lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia and does not correlate with p65 NF-kappaB activation. Modern Pathology, 19, 891-898. doi:10.1038/modpathol.3800609
[28]	Pham, L.V., Tamayo, A.T., Yoshimura, L.C., et al. (2003) Inhibition of constitutive NF-kappa B activation in mantle cell lymphoma B cells leads to induction of cell cycle arrest and apoptosis. Journal of Immunology, 171, 88-95.
[29]	Stoffel, A. (2005) The NF-kappaB signalling pathway: A therapeutic target in lymphoid malignancies? Expert Opinion on Therapeutic Targets, 9, 1045-1061. doi:10.1517/14728222.9.5.1045
[30]	Konturek, P.C., Konturek, S.J., Pierzchalski, P., et al. (2001) Cancerogenesis in Helicobacter pylori infected stomach—Role of growth factors, apoptosis and cyclooxygenases. Medical Science Monitor, 7, 1092- 1107.
[31]	Hazar, B., Ergin, M., Seyrek, E., et al. (2004) Cyclooxygenase-2 (Cox-2) expression in lymphomas. Leukemia and Lymphoma, 45, 1395-1399. doi:10.1080/10428190310001654032
[32]	Paydas, S., Ergin, M., Erdogan, S. and Seydaoglu, G. (2007) Cyclooxygenase-2 expression in non-Hodgkin’s lymphomas. Leukemia and Lymphoma, 48, 389-395. doi:10.1080/10428190601059787
[33]	Phipps, R.P., Ryan, E. and Bernstein, S.H. (2004) Inhibition of cyclooxygenase-2: A new targeted therapy for B-cell lymphoma? Leukemia Research, 28, 109-111. doi:10.1016/S0145-2126(03)00260-1
[34]	Wun, T., McKnight, H., Tuscano, J.M. (2004) Increased cyclooxygenase-2 (COX-2): A potential role in the pathogenesis of lymphoma. Leukemia Research, 28, 179-190. doi:10.1016/S0145-2126(03)00183-8
[35]	Yamamoto, S., Yamamoto, K., Kurobe, H., et al. (1998) Transcriptional regulation of fatty acid cyclooxygenases-1 and -2. International Journal of Tissue Reactions, 20, 17-22.
[36]	Yang, H., Zuo, X., Zhang, K., et al. (2006) Expression of cyclooxygenase-2 and proliferating cell nuclear antigen in gastric mucosa-associated lymphoid tissue lymphoma. World Chinese Journal of Digestology, 12, 1178-1182.
[37]	Wu, X., Han, S., Wan, L., et al. (2007) BCL10 and NF-kB are prognostic factors in gastric MALT lymphomas. Chinese Journal of General Surgery, 22,172-175.
[38]	Park, S.W., Sung, M.W., Heo, D.S., et al. (2005) Nitric oxide upregulates the cyclooxygenase-2 expression through the cAMP-response element in its promoter in several cancer cell lines. Oncogene, 24, 6689-6698. doi:10.1038/sj.onc.1208816
[39]	Wotherspoon, A.C., Doglioni, C., Diss, T.C., et al. (1993) Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pylori. Lancet, 342, 575-577. doi:10.1016/0140-6736(93)91409-F
[40]	Sawhney, M., Rohatgi, N., Kaur, J., et al. (2007) Expression of NF-kappaB parallels COX-2 expression in oral precancer and cancer: Association with smokeless tobacco. International Journal of Cancer, 120, 2545-2556. doi:10.1002/ijc.22657
[41]	Yang, G.Z., Li, L., Ding, H.Y., Zhou, J.S. (2005) Cyclooxygenase-2 is over-expressed in Chinese esophageal squamous cell carcinoma, and correlated with NF-kappaB: An immunohistochemical study. Experimental and Molecular Pathology, 79, 214-218. doi:10.1016/j.yexmp.2005.09.002